Comparison of Three Sample Preparation Procedures for the Quantification of L-Arginine, Asymmetric Dimethylarginine, and Symmetric Dimethylarginine in Human Plasma Using HPLC-FLD by Schou-Pedersen, Anne Marie Voigt & Lykkesfeldt, Jens
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Comparison of Three Sample Preparation Procedures for the Quantification of L-
Arginine, Asymmetric Dimethylarginine, and Symmetric Dimethylarginine in Human
Plasma Using HPLC-FLD
Schou-Pedersen, Anne Marie Voigt; Lykkesfeldt, Jens
Published in:






Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Schou-Pedersen, A. M. V., & Lykkesfeldt, J. (2018). Comparison of Three Sample Preparation Procedures for
the Quantification of L-Arginine, Asymmetric Dimethylarginine, and Symmetric Dimethylarginine in Human
Plasma Using HPLC-FLD. Journal of Analytical Methods in Chemistry, 2018, [6148515].
https://doi.org/10.1155/2018/6148515
Download date: 03. Feb. 2020
Research Article
Comparison of Three Sample Preparation Procedures for the
Quantification of L-Arginine, Asymmetric Dimethylarginine, and
Symmetric Dimethylarginine inHuman PlasmaUsingHPLC-FLD
Anne Marie Voigt Schou-Pedersen and Jens Lykkesfeldt
Experimental Pharmacology and Toxicology Laboratory, Department of Veterinary and Animal Sciences, Faculty of Health and
Medical Sciences, University of Copenhagen, Ridebanevej 9, 1870 Frederiksberg C, Denmark
Correspondence should be addressed to Jens Lykkesfeldt; jopl@sund.ku.dk
Received 29 August 2017; Accepted 26 November 2017; Published 1 February 2018
Academic Editor: Hana Sklenarova
Copyright © 2018 Anne Marie Voigt Schou-Pedersen and Jens Lykkesfeldt. 0is is an open access article distributed under the
Creative CommonsAttribution License, which permits unrestricted use, distribution, and reproduction in anymedium, provided
the original work is properly cited.
Increased asymmetric dimethylarginine (ADMA) in human plasma has been associated with reduced generation of nitric oxide,
leading to atherosclerotic diseases. ADMA may therefore be an important biomarker for cardiovascular disease. In the present
study, three sample preparation techniques were compared regarding the quanti9cation of L-arginine and ADMA in human
plasma: (A) protein precipitation (PP) based on aqueous trichloroacetic acid (TCA), (B) PP using a mixture of ammonia and
acetonitrile, and (C) solid-phase extraction (SPE). 0e samples were analysed by using high-performance liquid chromatography
with <uorescence detection (HPLC-FLD). 0e analytical performance of (A) was comparable with that of (C), demonstrating
recoveries of >90%, coe?cient of variations (CVs, %) of <8, and a resolution (Rs) between ADMA and symmetric dimethy-
larginine (SDMA) of 1.2. (B) was disregarded due to recoveries below 75%. (A) was validated with good results regarding linearity
(>0.994), precision (<5%), and sensitivity (lower limit of quanti9cation (LLOQ)) of 0.14 µMand 12 nM for L-arginine and ADMA,
respectively. Due to the simplicity and speed of procedure (A), this approach may serve as preferred sample preparation of human
plasma samples before HPLC-FLD in providing important information regarding elevated ADMA concentrations.
1. Introduction
Nitric oxide (NO) is important in numerous biological
processes including the relaxation of smooth muscles and
inhibition of platelet aggregation [1]. 0e endothelial nitric
oxide synthase (eNOS) enzyme is involved in mediating
vasodilation in vascular endothelium due to its role in the
conversion of L-arginine to L-citrulline and NO, the latter
inducing vasodilation. NG,NG-dimethyl-L-arginine (asym-
metric dimethylarginine, ADMA) is a metabolic by-product
from protein modi9cation, and due to its similarity with
L-arginine, ADMA is a competitive inhibitor of eNOS [2].
Increased concentrations of ADMA have been found to
correlate with impaired endothelial vasodilation in several
clinical studies possibly leading to the development of
atherosclerotic diseases [3–5], and ADMA is considered to
be an important biomarker.0e similar NG,NG′-dimethyl-L-
arginine, SDMA, is not an inhibitor of eNOS but competes
with L-arginine in cellular uptake [6]. 0e reliability of
ADMA as a biomarker of endothelial dysfunction is de-
pendent on its precise analytical quanti9cation, which is
challenging due to the narrow concentration range found in
healthy individuals [7].
A sample preparation step is often required before
chromatographic analysis in order to separate the analytes of
interest from proteins and other possible interferences in
plasma [8]. Commonly used sample preparation techniques
include PP, solid-phase extraction (SPE), and liquid-liquid
extraction (LLE) [9]. Regarding the analysis of L-arginine,
ADMA, and SDMA in human plasma, sample preparation
by SPE using cation-exchange columns is the currently
preferred approach [10–13]. A few publications exist for
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quanti9cation of L-arginine, ADMA, and SDMA, where
simple PP has been performed with 5-aminosalicylic acid
[14], ethanol [15], or acetonitrile/ammonia [16]. However,
these methods still consist of several steps including lyo-
philisation or evaporation.
After sample preparation, the separation and sub-
sequent detection of L-arginine, ADMA, and SDMA are
often performed using HPLC-FLD after pre- or post-
column derivatization of L-arginine and ADMA with
a <uorescent tag. In most studies, the <uorophore ortho-
phthalaldehyde-mercaptoethanol (OPA-ME) has been used
[13–15, 17, 18], but 6-aminoquinolyl-N-hydroxysuccinimidyl
carbamate (AccQ Fluor reagent, Waters) has also been
employed [11, 19]. Besides HPLC-FLD, additional separation
and detection principles may come into play, for example,
capillary electrophoresis coupled to UV [20, 21] or HPLC
coupled to a mass spectrometer [22, 23]. Quanti9cation
based on commercial ELISA kits has been described
lately, but may overestimate the concentration of ADMA,
and is typically less precise [1].
Since current analytical methods described in the literature
for quanti9cation of L-arginine and ADMA involve relatively
complicated and time-consuming sample preparation pro-
cedures, the aim of the present study was to investigate
whether simple and fast PP before quanti9cation of the
biomarkers L-arginine, ADMA, and SDMA in human plasma
may result in acceptable analytical performance evaluated by
the FDA guideline for bioanalytical validation [24]. A partial
validation of SDMA was performed, since L-arginine and
ADMA were our primary goals of interest. Two diMerent PP
approaches were compared with state-of-the-art SPE cleanup
regarding resolution, recovery, precision, simplicity, and cost.
L-arginine, ADMA, and SDMA were labelled with the
<uorescent tag, OPA-ME, and the derivatives were separated
by using a reversed-phase HPLC-FLD method.
2. Materials and Methods
2.1. Instrumentation. All separations were performed on
a Dionex Ultimate 3000 (0ermoscienti9c, Waltham, MA,
USA) coupled to a Dionex <uorescence detector containing
a micro <ow cell (2 µl). Chromeleon 7.2 was used for data
acquisition and analysis.
2.2. Materials. L-arginine (>99%), NG,NG′-dimethyl-L-
arginine di(p-hydroxyazobenzene-p′-sulfonate) (SDMA),
perchloric acid (PCA), potassium tetraborate, ortho-phtha-
laldehyde (OPA), and 2-mercaptoethanol (ME) were obtained
from Sigma-Aldrich (Steinheim, Germany). NG,NG-dimethyl-
L-arginine hydrochloride (ADMA, >98%) was purchased from
Cayman Chemical Company (Ann Arbor, MI, USA). Di-
potassium hydrogen phosphate, potassium-dihydrogen
phosphate, trichloroacetic acid (TCA), perchloric acid (PCA),
hydrochloric acid (37%), ammonia (25%), ortho-phosphoric
acid (85%), methanol, sodium hydroxide, and acetonitrile were
purchased from Merck (Darmstadt, Germany). Oasis MCX
mixed-mode SPE columns (30mg, 1ml) were kindly supplied
by Waters Denmark.
2.3. Calibration Standards. Calibration stock solutions of
2.0mM of L-arginine and 6.05mM of ADMA and SDMA
were prepared in 60% methanol and stored at −20°C until
use. Working calibration standards of L-arginine, ADMA,
and SDMA were prepared in 10mM HCl in concentrations
ranging from 0.5 µM to 15 µM for L-arginine and from
12 nM to 0.5 µM for ADMA and SDMA. Calibration stan-
dards were analysed in duplicate.
2.4. Sample Preparation. 0ree diMerent sample preparation
techniques (A), (B), and (C) were evaluated by using human
plasma obtained from one person. 0e procedures are brie<y
described in the following: (A) PP was performed on 50 µl
human plasma by adding 150µl cold 1M TCA dissolved in
water. After 10min on ice, centrifugation was performed at
4°C with 16,000g for 10min. 0e resulting supernatant was
neutralised with equimolar amounts of 1M aqueous NaOH
and subsequently analysed. (B) PP was performed by adding
150µl of a cold mixture of ammonia and 25% acetonitrile (10 :
90, v/v) to 50 µl human plasma. After 10min on ice and
centrifugation at 4°C with 16,000g in 10min, the supernatant
was analysed directly. (C) Oasis MCX SPE cartridges were
initially washed with 300µl methanol and then with 300µl
0.1MHCl. Fifty microliters of human plasma was diluted with
150 µl of 4% (v/v) phosphoric acid and loaded onto the SPE.
0e SPE cartridge was then washed with 300µl of methanol
and 300µl of 0.1M HCl. 0e analytes were eluted with 400µl
of a mixture of ammonia and 25%/1M NaOH/water/MeOH
(10 : 0.5 : 40 : 50, v/v).0e solvent was removed by evaporation
with nitrogen at a temperature of 60°C to 70°C. 0e residue
was dissolved in 50µl of 60% methanol and analysed.
Recoveries in % were determined for each sample
preparation technique by fortifying the concentration of
L-arginine and ADMA in a human plasma sample with
calibration standard and measuring the concentration in the
spiked sample in relation to the concentration measured in
the unspiked sample plus the added calibration standard
concentration. 0e retention times for L-arginine, ADMA,
and SDMA were veri9ed in each sample preparation pro-
cedure by 10 times forti9cations with calibration standards.
2.5. Chromatographic Separation and Detection. In order to
detect L-arginine, ADMA, and SDMA, precolumn de-
rivatization was performed automatically by mixing 3 µl of
borate buMer (400mM, pH 10) with 1 µl of 75mM OPA
dissolved in methanol and 1 µl of 56mM aqueous ME at 4°C.
0e mixture of sample and reagents was incubated at 4°C for
10 s. Of the resulting mixture, 3 µl was injected onto the
column.
0e chromatographic conditions used in the current
method were inspired by a previously published method for
the quanti9cation of L-arginine, ADMA, and SDMA [13].
Separation of the OPA-ME derivatives of L-arginine,
ADMA, and SDMA was performed at a temperature of 40°C
using a Phenomenex Gemini C18 column with the di-
mension 150× 4.6mm and a particle size of 5 µm. Prior to
the analytical column, a C18 guard column with the di-
mension 4× 3mmwas placed.0emobile phase A consisted
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of 50mM potassium phosphate (pH 6.5) containing 14%
(v/v) acetonitrile. 0e mobile phase B was 60% (v/v) ace-
tonitrile. Isocratic separation was performed with 100%
mobile phase A at a <ow rate of 1.2ml/min. After 20min, the
mobile phase was switched to 100% B in 3min to wash oM
late-eluting compounds. Finally, the column was re-
equilibrated for 7min giving a total run time of 30min.
0e <uorescent OPA-ME derivatives of L-arginine, ADMA,
and SDMA were detected at an excitation wavelength of
340 nm and an emission wavelength of 455 nm. Retention
times for the L-arginine, ADMA, and SDMA derivatives
were 10.5, 18.1, and 19min, respectively.
2.6. Method Validation. Robustness was initially tested for
procedure (A) applying diMerent time intervals (2, 8, 10, and
12min) for performing PP. 0ereafter, the selected sample
preparation technique, procedure (A), combined with the
developed chromatographic method was validated with
respect to linearity, recovery, precision, and sensitivity
(taken as LLOQ) on a human plasma sample [24]. 0e
recovery was tested at three concentration levels corre-
sponding to approximately 30, 60, and 90% of the initial
concentration of L-arginine and ADMA. 0e average re-
covery should be within 15% of the nominal value. Intra-
assay variability was tested on human plasma (n� 6).
Interassay variability was evaluated by analysing human
plasma samples in triplicate on three diMerent days (n� 9). A
coe?cient of variation (CV, %) of up to 15% was considered
acceptable. LLOQ was estimated for L-arginine and ADMA
by diluting human plasma with PBS buMer (pH 7.4) to the
expected LLOQ, and recovery and precision was determined
on these samples (n� 6). A precision and recovery range of
no more than 20% variation was considered to be acceptable
at LLOQ [24]. Upper limit of quanti9cation (ULOQ) was
taken as the highest concentration from the calibration curve.
0e stability for extracted human plasma samples and
calibration standards was tested for L-arginine and ADMA
at 4°C. 0e long-term stability was further assessed for
human plasma at −80°C and for calibration stock solutions at−20°C. All stability tests were performed in triplicate. Ac-
ceptable stability means that at least 90% of the initial
amount was found at a given time point.
2.7. Quality Control Samples. Blood samples were obtained
from six apparently healthy individuals after informed
consent but without collection of any data on the in-
dividuals. 0e use of human blood for quality control
purposes is not subject to ethical approval in Denmark. 0e
blood was collected in VacutainerTM collection tubes con-
taining K3-EDTA from Becton Dickinson (Franklin Lakes,
NJ, USA) and centrifuged at 2000 g for 5min at 4°C. 0e
resulting plasma was stored in aliquots at −80°C and used for
veri9cation of the analytical method.
3. Results
3.1. Optimisation of Sample Preparation Procedures. Preliminary
studies of diMerent PPs were performed. Zinellu et al.
showed that the recoveries of L-arginine and ADMA were
low using 100% acetonitrile [21]. Acetonitrile containing
TCA, PCA, or ammonia was tested. Furthermore, aqueous
solutions of TCA and PCA were investigated. PP with PCA
was not found to extract L-arginine and ADMA very e?-
ciently as opposed to aqueous TCA, which showed promising
results. However, decreasing concentrations of L-arginine and
ADMA were found in the sample solutions, and a neutrali-
zation step was therefore added. DiMerent ratios of 25%
ammonia and acetonitrile (10 : 90, 20 : 80, and 30 : 70, v/v) were
tested, but increasing the percentage of ammonia did not
improve recovery markedly; thus, the 10 : 90 (v/v) ratio was
retained, procedure (B).
In the development of the SPE cleanup, (C), adding PBS
buMer (pH 7.4) to plasma in a ratio of 3 : 1 as described in
previous studies was found to clog the Oasis MCX column,
and therefore, human plasma was diluted with 4% phos-
phoric acid as described by the manufacturer’s protocol.
According to a recent publication by de Jong and Teerlink
[25], the elution solvent for L-arginine and ADMA using
Oasis MCX SPE cartridges was optimised to a mixture of
concentrated ammonia/1M NaOH/water/methanol (10 :
0.5 : 40 : 50, v/v), and this elutionmixture was selected for the
current SPE cleanup.
3.2. Results from Sample Preparation Procedures
(A), (B), and (C)
3.2.1. Recovery and Precision. Working calibration stan-
dards of L-arginine and ADMA dissolved in 10mM HCl
were used to construct a calibration curve for the com-
parison of the three sample preparation techniques (A), (B),
and (C). Recoveries in % for L-arginine and ADMA were
determined and are shown in Table 1.0e average recoveries
obtained for procedures (A) and (C) were higher than 90%
for both L-arginine and ADMA, and therefore acceptable.
Furthermore, procedure (A) showed satisfactory recoveries
at three concentration levels. Procedure (B) demonstrated
recoveries of less than 75%. 0e precision expressed as “CV,
%” was estimated from the recovery experiments and was
found to be less than 8% for the three tested sample prepa-
ration procedures (A–C).
3.2.2. Chromatographic Performance. Figures 1(a)–1(c)
show examples of chromatograms obtained after each of
the three diMerent sample preparation procedures (A), (B),
and (C). No major diMerences were observed between the
three obtained chromatograms. 0e resolution between
ADMA and SDMA in procedure (A) was determined to be
1.2 as compared to the two other procedures, where Rs was
below 1.
3.2.3. Validation of Procedure (A). 0e robustness of pro-
cedure (A) was initially tested by performing PP on ice with
diMerent time points (2, 8, 10, or 12min). 0e robustness
study did not show any diMerence between the obtained
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concentrations of L-arginine and ADMA; thus, this step was
not found to be critical.
Validation results can be found in Tables 1 and 2.
Obtained recoveries were from 91.5± 3.03% up to 113±
8.21%. Intra-assay variation (CV, %) was 3.2 for L-arginine,
3.2% for ADMA, and 4.2% for SDMA, whereas interassay
variation was observed to be 5.0% for L-arginine, 3.3% for
ADMA, and 3.8% for SDMA. At LLOQ, the found recoveries
were 114% for L-arginine and 92% for ADMA and the intra-
assay variations were 21% for L-arginine and 19% for ADMA
(n� 6) (data not shown). L-arginine, ADMA, and SDMA
were quanti9ed in quality control samples using procedure
(A) and the developed HPLC method. An average con-
centration of 64.1± 10.3 µM for L-arginine, 0.27± 0.02 µM
for ADMA, and 0.57± 0.09 µM for SDMA was obtained
(n� 6).
Table 3 shows the stability at 4°C of a calibration standard
prepared at ULOQ and of human plasma after extraction
with procedure (A). Storage of calibration standards at 4°C is
not recommended for more than 24 hours, whereas the
stability of prepared human plasma at 4°C is acceptable for
up to 48 h. Human plasma stored at −80°C and calibration
stock solutions stored at −20°C are considered to be stable
for at least 6 months.
4. Discussion
4.1. Comparison of Sample Preparation Procedures (A), (B),
and (C). In all three sample preparation procedures, base-
line resolution could not be obtained between ADMA and
SDMA, and both ADMA and SDMA were surrounded by
larger unknown peaks. Optimisation of the HPLC method
could possibly have improved the resolution, especially in
the chromatogram obtained after performing procedure (C).
However, in order to compare the sample preparation
procedures, it was considered necessary to use exactly the
same chromatographic method for all three procedures.
Since baseline resolution was not attained, there is a chance
of experiencing interference from adjacent peaks. However,
the average concentration of ADMA found in the quality
control samples did not indicate interference, since the
observed concentrations were in the lower end of the ADMA
range stated in literature [26]. Furthermore, the precision of
the current method was very good (CV< 5%). In addition, it
was possible to separate ADMA from SDMAwith acceptable
resolution, supporting that a reliable analytical method was
developed.
0e selectivity was surprisingly not markedly increased
by performing the SPE cleanup (Figure 1(c)), although
the observed unknown peaks are lower as compared to
Figure 1(a). 0e minor improvement in selectivity obtained
by the SPE cleanup may be explained by the limited capacity
of SPE cartridges.
0e supernatants obtained after performing procedures
(A) and (C) were clear, as opposed to the relatively cloudy
solution obtained after procedure (B), which further lead to
recoveries below 75%. Zinellu et al. used a 10 : 90 mixture of
ammonia : acetonitrile for PP. However, they performed
additional steps of 9ltration and concentration of their
samples, which allegedly improved the recovery.
0e main diMerence between sample preparation pro-
cedures (A) and (B) in relation to (C) is that laborious steps
in procedure (C) have to be performed, resulting in a di-
minished throughput of samples per day. 0is is not de-
sirable in a clinical laboratory, where research studies often
comprise many samples. In addition, the probability of
introducing errors and the risk of analyte loss during per-
formance of the several steps in the SPE cleanup makes this
approach less preferable. Furthermore, the cost-eMectiveness
of (C) with acquisition of SPE cartridges and an increased
workload in the laboratory are estimated to be around 10
Euros per sample, which is less attractive when compared to
(A) with an estimated cost of 3 Euros per sample.
One argument often stated for performing the laborious
SPE cleanups is the decreased contamination of the HPLC
column and/or detector. However, when using procedure
(A) and the developed analytical method including
a washing step of the column, the pressure increase was not
considered to be critical (around 5 bars per 100 human
plasma samples) and could be eliminated by changing the
precolumn. 0e same HPLC column has been used for
several hundred human plasma samples without de-
terioration of the resolution.
4.2.Validationof SamplePreparationProcedure (A). Overall,
the validation results were acceptable. 0e recoveries for
L-arginine were generally found to be above 100%. 0e
reason for this could be that the calibration standard used for
spiking in the recovery experiment was dissolved in 10mM
Table 1: Determined average concentrations of L-arginine and ADMA in human plasma±SD (n� 3) and average recovery ±SD (n� 3) at
three concentration levels obtained with sample preparation procedure (A). Recovery values in % given as mean± SD (n� 3) obtained for
procedure (B) and procedure (C) are shown for comparison.
Human plasma,
mean ± SD (µM) Procedure A Procedure B Procedure CAdded
(µM)
Measured,
mean± SD (µM) Recovered,mean± SD (%) Recovered,mean± SD (%) Recovered,mean± SD (%)
L-arginine 65.3± 2.09 20 94.3± 10.1 113± 8.21 — —40 115± 3.20 109± 2.78 68.4± 5.50 118± 3.62
60 138± 8.67 110± 6.92 — —
ADMA 0.40± 0.013 0.1 0.47± 0.030 91.5± 3.03 — —0.2 0.59± 0.070 98.0± 7.07 73.5± 4.22 94.7± 8.46
0.3 0.70± 0.032 98.9± 4.55 — —



































































































































Figure 1: Representative chromatograms obtained from the analysis of human plasma using (a) procedure (A), PP with aqueous TCA; (b)
procedure (B), PP with amixture of acetonitrile and ammonia (90 : 10); and (c) procedure (C), SPE cleanup with Oasis MCX. Insets: zoom of
the ADMA and SDMA peaks at 18.1 and 19.0min, respectively.
Journal of Analytical Methods in Chemistry 5
HCl, which apparently aMected the observed recovery of
L-arginine. However, the level of L-arginine in human
plasma has not been observed to deviate from literature
values; thus, the issue is considered to be related to the setup
of the recovery experiment. Regarding LLOQ, the found
recovery for L-arginine was just above the acceptance cri-
terion of 20%. However, since the LLOQ for L-arginine is
well below the expected concentration of L-arginine in
human plasma, the marginally higher variation for L-arginine
at LLOQ is not anticipated to have any practical importance.
L-arginine, ADMA, and SDMA concentrations for the
quality controls can be found in Table 2 (n� 6). In the lit-
erature, the L-arginine concentration in human plasma has
been reported with an interval of 59.4 to 95.6 µM (n� 1141)
[27]. Horowitz and Heresztyn have reported ADMA mean
concentrations from 0.30 to 2.38 µM in plasma or serum
using diMerent analytical techniques [26]. Teerlink reported
ADMA and SDMA in plasma from 2311 patients with an
average concentration of 0.50 µM for ADMA and 0.53 µM
for SDMA. 95% con9dence intervals for ADMA and SDMA
were reported to 0.39–0.63 µM and 0.38–0.73 µM, re-
spectively [7]. 0e obtained results for the quality control
samples for L-arginine are within the reported range, al-
though in the lower end. 0e found ADMA and SDMA
concentrations in the current study are close to the literature
values, although a bit lower for ADMA. However, the sample
size was also quite small.
5. Conclusions
0e analytical performance of sample preparation pro-
cedure (A) consisting of simple PP with TCA is considered
to be superior to procedure (B) and similarly as good as
performing a SPE cleanup, procedure (C) in quantifying
L-arginine, ADMA, and SDMA in human plasma using
HPLC-FLD. 0e developed HPLC-FLD method with
sample preparation procedure (A) proved to be both ac-
curate with recoveries ranging from 91.5± 3.03% to 113±
8.21% and precise with CVs of no more than 5%. Fur-
thermore, the sensitivity was acceptable with an LLOQ of
0.14 µM for L-arginine and 12 nM for ADMA. 0e easy
sample preparation in our analytical method allows for high
throughput of samples from clinical research studies in the
quanti9cation of L-arginine, asymmetric dimethylarginine
(ADMA), and symmetric dimethylarginine (SDMA) in
plasma. ADMA is important in the preliminary evaluation
of endothelial dysfunction in humans.
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